Related medicinesRusfertide
Where it comes from
- Made in
- Hepatocytes of the liver
- Sent out by
- Rising iron stores and inflammation (interleukin-6) push it up; the need for new red cells, signalled by erythroferrone, pulls it down
- Acts on
- The gut lining cells that absorb iron
- The macrophages that recycle iron
- The liver cells that store iron
What it does
- Locks iron inside cells and out of the blood
- Explains the anaemia of chronic disease: inflammation raises hepcidin and starves red cells of iron 1
- Too little of it, as in hereditary haemochromatosis, lets iron overload the organs
In medicine
- Rusfertide, a hepcidin mimetic, is approved in the United States (2026) for polycythaemia vera, to curb the excess of red cells 3
- Hepcidin blood tests are used in research to tell iron deficiency from inflammation 1
- The Iron Metabolism area of the Evigenics report reads HFE, the gene upstream of hepcidin
Beyond the body’s own use
- Rusfertide, injected weekly, cut the need for blood removal in the 293-patient phase 3 VERIFY trial: 77% of those treated needed no phlebotomy against 33% on placebo, and fewer than half as many were still above a haematocrit of 45% 2
- Blocking hepcidin is the opposite bet, tried for the anaemia of chronic disease and of kidney disease, where too much of it starves red cells of iron; nothing in that line is approved
- The hepcidin blood test remains mainly a research measure, because the assays do not agree well enough to set a reference range 1; ferritin and transferrin saturation are still the clinical measures of iron
Sources
This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.